Date: 2015-04-09
Type of information: Nomination
Compound:
Company: Atyr Pharma (USA - CA)
Therapeutic area: Cancer - Oncology - Genetic diseases - Rare diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On April 9, 2015, aTyr Pharma, a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address rare diseases, announced that it has named Marcy Graham as Vice President, Investor Relations and Corporate Communications. Ms. Graham was previously Executive Director of Investor Relations and Corporate Communications at Ambit Biosciences, where she built the company’s investor relations program from their initial public offering to their eventual acquisition. In her role at aTyr, Ms. Graham will spearhead investor relationship management while positioning the company as a global leader in the development of first-in-class, Physiocrine-based medicines to address severe, rare diseases. Marcy Graham is the former Executive Director of Investor Relations and Corporate Communications for Ambit Biosciences, a small cap biopharmaceutical company focused on developing therapies for patients with an acute form of leukemia. During her tenure at both Ambit and Genoptix, Ms. Graham built and managed investor relations programs for each company as they entered the public markets through initial public offerings.
Financial terms:
Latest news:
